60 participants
Savolitinib vs. Sunitinib in MET-driven PRCC.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-14
- Start Date:
- 2017-07-25
- Completion:
- 2019-08-18
Conditions
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Urologic Neoplasms
- Kidney Diseases
- Neoplasms by Site
- Enzyme Inhibitors
- Protein Kinase Inhibitors
Interventions
- DRUG